Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587087 | 0.96 | KMT2A (0.39) | CYP2C9CYP2C19KMT2AUSP30NOTUM | |
| SCHEMBL587216 | 0.91 | KMT2A (0.41) | CYP2C9CYP2C19KMT2AUSP30OPRL1 | |
| SCHEMBL580828 | 0.89 | CYP2C9 (0.50) | CYP2C9CYP2C19KMT2ANOTUMEPHX2 | |
| SCHEMBL581326 | 0.89 | TP53 (0.41) | KMT2ANOTUMCHRM3 | |
| SCHEMBL582014 | 0.87 | NOTUM (0.43) | KMT2ANOTUMOPRL1MAPTEPHX2 | |
| SCHEMBL581895 | 0.85 | NOTUM (0.33) | NOTUM | |
| SCHEMBL580684 | 0.85 | NOTUM (0.42) | KMT2ANOTUMMAPT | |
| SCHEMBL587829 | 0.85 | DPP4 (0.38) | KMT2ANOTUMMAPT | |
| SCHEMBL580928 | 0.84 | CYP2C19 (0.39) | CYP2C9CYP2C19KMT2ANOTUMOPRL1 | |
| SCHEMBL3078690 | 0.84 | MGLL (0.38) | CYP2C9CYP2C19KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| CN-102459246-A | Isoxazol-3 (2H) -one analogs as therapeutic agents | ASTRAZENECA AB | 2012-05-16 | — | — | CN | disclosed |
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | CYP2C9 472/4885CYP2C19 966/4885KMT2A 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.